SPONSORSHIP ALLIANCE NEWS
Prostate cancer is a major health concern. One in eight men will be diagnosed with prostate cancer at some point in their life. Other than skin cancer, it is the most common form of cancer in men—the American Cancer Society estimates there will be nearly 300,000 new cases of prostate cancer this year in the U.S.—and it is the second-deadliest behind lung cancer. The American Cancer Society, though, does report some good news: From 1993 to 2013, prostate cancer's death rate was cut in half likely due to earlier detection and treatment advances.
To spotlight the country's top prostate cancer specialists, Newsweek is partnering with Statista for the first annual ranking of America's Best Prostate Cancer Oncologists & Surgeons. The ranking recognizes the top 150 individuals in each of the two categories.
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to standard-of-care chemotherapy improved progression-free survival (PFS) in patients with oligometastatic pancreatic cancer. Findings from the multicenter EXTEND trial, published today in the Journal of Clinical Oncology, were first presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.
Join Vision RT in our booth at ASTRO 2024 to see live demos of surface guidance products for every step of the workflow: Sim, Plan, Treat, Dose. As the founders of SGRT, we continue to innovate -- now delivering clearance mapping for better planning and dose visualization. Don't miss seeing the market leading SGRT solutions that improve patient safety and deliver time savings. As an added treat, we'll customize a chocolate bar for you while you watch the demos!
Conclusion: For the SRS treating single brain metastasis, all three treatment devices, ZAP-X system, CyberKnife G4 system, and GammaKnife system, could meet clinical treatment requirements. The new ZAP-X platform could provide a high-quality plan equivalent to or even better than CyberKnife and Gamma Knife, with ZAP-X presenting a certain dose advantage, especially with a more conformal dose distribution and better protection for brain tissue. As the ZAP-X systems get continuous improvements and upgrades, they may become a new SRS platform for the treatment of brain metastasis.
The Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) acknowledged that AstraZeneca’s Imfinzi (durvalumab) met the primary endpoint of event-free survival (EFS) in the treatment of resectable non-small cell lung cancer (NSCLC) based on the AEGEAN Phase III trial results with an overall tolerable safety profile.
Researchers from multiple clinical programs presented scientific evidence in 37 oral and poster presentations confirming the efficacy and feasibility of the RefleXion® X1 machine with SCINTIX® biology-guided radiotherapy at the 2024 American Association of Physicists in Medicine (AAPM) Annual Meeting.
First and only EGFR inhibitor and targeted treatment to show benefit in Stage III setting, extending progression-free survival by more than three years .
57% of patients treated with Imfinzi were alive at three years in ADRIATIC Phase III trial.
Artificial intelligence (AI) has the potential to shape nearly every aspect of our lives – including cancer care. At MD Anderson, we see the opportunities and risks associated with the emergence of AI and an ever-increasing amount of data being generated by our cancer research, patient care and clinical operations.
Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support standard use of the more precise intensity-modulated radiotherapy (IMRT) over the alternative 3D-conformal radiotherapy (3D-CRT) for patients with unresectable, locally advanced non-small cell lung cancer (NSCLC). The study, published today in JAMA Oncology, revealed fewer side effects with IMRT, with similar survival outcomes.
Varian, along with Cureus.com, is sponsoring a "CT or CBCT Guided Online Adaptive Radiotherapy (ART) Clinical Case Reports" publishing competition. Eligible case reports will illustrate online ART based on daily CT or CBCT images. Cases may report on ART anywhere in the body, and should highlight a significant advantage of online ART, show the potential to change RT practice, or show that daily ART allows clinicians to treat more effectively compared to a non-adaptive approach. Competition submissions should clearly illustrate, with images, analyses, and clinical outcomes, the advantages of CT/CBCT-guided online ART compared to non-ART treatment.
Submission Deadline: Tuesday, July 23, 2024
Submission site closes at 5:00 pm ET
For questions contact David Schaal at david.schaal@varian.com
New technology presents new opportunities in patient care, something that Yogesh Kumar, Ph.D., knew well when he began researching the use of machine-learning software in cancer treatment. When he received this year’s Mary Ann Harvard NextGen Scholar Award for his work integrating artificial intelligence into radiotherapy, he knew he was on the right track.
Congratulations to Professor Alexander Muacevic, Dr. Markus Kufeld and the team at ERCM.
Congratulations to Alexander Muacevic, Antonio Santacroce, Felix Ehret and the rest of the team at European Radiosurgery Center - Munich (ERCM) on publishing the first use of ZAP-X gyroscopic radiosurgery for uveal melanoma.
In the overall trial population, survival results numerically favoured AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan but did not reach statistical significance.
TROPION-Lung01 previously met the dual primary endpoint of progression-free survival in the overall trial population.
Results support applications currently under review by regulatory authorities globally including in the US and EU.
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Elekta and MIM Software Inc., a leading provider of medical imaging management and artificial intelligence solutions, recently acquired by GE HealthCare, announce their collaboration to combine best-of-breed solutions for advanced treatment planning in the delivery of radiation therapy. The strategic collaboration aims to accelerate innovation in software solutions that will benefit clinics with improved workflows, higher throughput, and enhanced user experience, while for patients, provide greater precision in their treatment and less time spent at the hospital.
AEx Rewind Webinar: SBRT for Central and Ultra-Central Early-Stage Inoperable Non-Small Cell Lung Cancer is now available on demand. This informative session explores treatment options for patients who are medically inoperable and have central or ultra-central lung cancer (CLC/UCLC). Don't miss this opportunity to gain valuable insights into managing CLC/UCLC patients through SBRT.
Future Brain Therapy: Cutting-edge radiotherapy device offers hope for Chinese brain tumor patients. recently received official treatment approval in China. Watch the news segment here.
A cost-effective, rapid deployment of state-of-the-art radiosurgery made possible with the vault-free, cobalt-free ZAP-X. Congratulations to the teams at Miami Cancer Institute and Baptist Health for initiating patient treatments in this entirely novel and pioneering setting. Learn more how ZAP-X creates elite neuro-oncology programs anywhere, everywhere. Visit https://zapsurgical.com/